Psoriatic arthritis (PsA) is a debilitating seronegative spondyloarthropathy associated with increased mortality risk, especially when there is a delay in diagnosis, but it remains underdiagnosed and inadequately treated. Although the clinical course varies, this progressive inflammatory disease often results in disabling pain and joint damage and has been shown to reduce life expectancy. Despite the availability of treatments for PsA and treatment guidelines, a significant percentage of treatment failures occur. Rheumatologists, dermatologists, and primary care physicians require education to improve the evidence-based application of available treatments. In addition, several new treatments with different mechanisms of action are in late-stage clinical development. Clinicians must develop an understanding of the immunologic and inflammatory pathophysiology of PsA, the mechanism of action of therapies, and their place in the treatment armamentarium so that they are prepared to apply these therapies in their practices. Arthur Kavanaugh, MD,Professor of Medicine; Director, Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, joined Medscape Rheumatology to discuss key highlights in PsA released at the American College of Rheumatology (ACR) conference, October 26-30, 2013.